Health Condition 1: K74- Fibrosis and cirrhosis of liver
Conditions
Interventions
None listed
Sponsors
Post Graduate Institute of Medical Education and Research PGIMER
Eligibility
Inclusion criteria
Inclusion criteria: ACLF patients: i. Age 18-80 years ii. Giving a positive consent
Exclusion criteria
Exclusion criteria: Patients with i. Human immunodeficiency virus infection ii. Pregnancy, iii. Previous liver or other organ transplantation iv. Known immunosuppressed states (steroid use in previous 6 months) and v. Those refusing to give consent will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the clinical and plasma proteomic profile between ACLF patients with culture-proven infections (bacterial and/or fungal) and ACLF patients without infectionsTimepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. Validation of results in next 3 months. Final data analysis 3 months. | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the clinical and plasma proteomic profile between ACLF patients with culture-proven bacterial infections and culture proven fungal infections.Timepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. ;To compare the clinical and plasma proteomic profile between survivors and non-survivors amongst patients with ACLF.Timepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. ;To compare clinical and proteomic profile between patients with culture-proven infections as a precipitant for ACLF and culture-proven infections as a complication during the course of ACLF.Timepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. ;To compare the proteomic profile between patients with different grades of ACLF.Timepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. ;To compare the proteomic profile between ACLF patients without infection and healthy controls.Timepoint: Recruitment & follow up of patients and simultaneous proteomic analysis for first 16 months. ;To validate the proteomic markers identified on primary analysis in the baseline samples of patients with ACLF.Timepoint: Validation of results from discovery phase during months 17-19. Final data analysis 3 months. | — |
Countries
India
Contacts
Public ContactDr Nipun Verma
PGIMER, Chandigarh
Outcome results
None listed